Recent molecular studies of NSCLC find that mutations of the EGFR gene are present in 10-20% of lung adenocarcinomas (ADC) and are associated with successful treatment with EGFR inhibitors [4],[5], whereas KRAS mutations are present in 20-30% of ADC and associated with non-response to EGFR inhibitors [4]-[6]. Here, EGFR is linked to lung adenocarcinoma.